ALK (ALKB.DC / OMX: ALK B) will publish its results for the first six months of 2025 in the morning…
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…
Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis…
Breakthrough Epigenetic Modulator LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon CancerDENVER, Aug. 14,…
Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during…
NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation…
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation…
Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical ProgressNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) --…
Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical ProgressNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) --…